AVROBIO

Company Presentation June 2020

Disclaimer

This presentation has been prepared by AVROBIO, Inc. ("AVROBIO") for informational purposes only and not for any other purpose. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and AVROBIO's own internal estimates and research. While AVROBIO believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and AVROBIO makes no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources. While AVROBIO believes its internal research is reliable, such research has not been verified by any independent source.

This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as "aims," "anticipates," "believes," "could," "designed to," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy, prospective products and goals, the therapeutic potential of our investigational gene therapies, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, potential regulatory approvals and the timing thereof, the potential impact of the COVID-19 outbreak on our clinical trial programs and business generally, as well as our plans and expectations with respect to the timing and resumption of any development activities that may be temporarily paused as a result of the COVID-19 outbreak. anticipated benefits of our gene therapy platform including potential impact on our commercialization activities, the

expected benefits and results of our implementation of the plato[™] platform in our clinical trials and gene therapy programs, the expected safety profile of our investigational gene therapies, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products, the market opportunity for and anticipated commercial activities relating to our investigational gene therapies, and statements regarding the Company's financial and cash position and expected cash reserves. Any such statements in this presentation that are not statements of historical fact may be deemed to be forward-looking statements.

Any forward-looking statements in this presentation are based on AVROBIO's current expectations, estimates and projections about our industry as well as management's current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forwardlooking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO's investigational gene therapies will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators or of encountering challenges in the enrollment or dosing in such clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato platform, the risk that our investigational gene therapies or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIO's investigational gene therapies, the risk that we will be unable to obtain and maintain regulatory

approvals for our investigational gene therapies, the risk that the size and growth potential of the market for our investigational gene therapies will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our development timeline and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our investigational gene therapies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in AVROBIO's most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO's subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Note regarding trademarks: plato is a trademark of AVROBIO. Other trademarks referenced in this presentation are the property of their respective owners.

Note regarding future updates: The statements contained in this presentation reflect our current views with respect to future evets, which may change significantly as the global consequences of the COVID-19 pandemic rapidly develop. Accordingly, we do not undertake and specifically disclaim any obligation to update any forward-looking statements.


AVROBIO

Our mission: Giving people with genetic disease freedom for life



Multiple programs in the clinic


10 patients dosed to date



IND: Investigational New Drug



Addressing multi-billion dollar market opportunity




CURRENT STANDARD OF CARE COSTS

Sources: Rombach S et al, Orphanet J Rare Dis, 2013; van Dussen L et al, Orphanet J Rare Dis, 2014; WAC pricing from Redbook; 2019 Net Sales from company annual and other reports * for Horizon's Procysbi oral therapy (delayed release cysteamine bitartrate) Note: Shire acquired by Takeda in 2019






Lifelong treatments vs. potential single-dose therapy





ERT: Enzyme Replacement Therapy; IV: Intravenous; HSC: Hematopoietic Stem Cells

Established ex vivo lentiviral approach





Fabry Disease

8



UNMET NEEDS:



Kidney function Unmet needs: proteinuria, polyuria, kidney failure

Goals for gene therapy in **Fabry disease**



Neuropathic pain

Cardiac function

Unmet needs: pain and burning sensations in hands and feet, pain crises

Unmet needs: left ventricular hypertrophy, fibrosis, heart failure



CNS complications

Unmet needs: TIA/stroke, depression, impaired executive function, white matter hyperintensities



Everyday burden of illness and life expectancy

Unmet needs: fatigue, inability to sweat, joint pain, abdominal pain, diarrhea, vomiting, cloudy vision, hearing loss, tinnitus, rash, angiokeratomas, biweekly infusions, shortened lifespan



Sources: Wanner C et al, Med Genetics and Metab, 2018; Burlina A, JIEMS, 2016 CNS: Central Nervous System; TIA: Transient Ischemic Attack

Two AVR-RD-01 Fabry clinical trials

9 patients dosed across Phases 1 and 2



Patients

n = 5 (fully enrolled) On ERT > 6 months prior to enrollment 18 - 50 year-old males

Key Objective

Safety and preliminary efficacy

Patients

n = 8-12 (4 patients dosed to-date) **Treatment-naive** 16 - 50 year-old males

Key Objectives

Safety and efficacy



July 2019 data presented, unless otherwise specified * Sponsored by FACTs team (Fabry Disease Clinical Research and Therapeutics) in Canada

Fabry
FAB-201 ←
Patient
Characteristic

		PATIENT 1	PATIENT 2	PATIENT 3	PATIENT 4
	Age of symptom onset / diagnosis	10 / 19 years	36 / 37 years	13 / 13 years	9 / 9 years
	Age dosed with AVR-RD-01	21 years	46 years	40 years	26 years
Fabry FAB-201Patient CharacteristicsTreatment-naïve Fabry patients	Mutation	c.1021G>A (p.E341K)	c.644A>G (p.N215S)	c.639+1G>T	c.833dupA
	Primary disease signs and symptoms	 Kidney disease Chronic pain GI symptoms Decreased cold sensation 	 Cardiac disease Peripheral neuropathy Chronic pain Increased tiredness GI symptoms Intermittent tinnitus Mild high frequency hearing loss Raynaud's syndrome 	 Kidney disease GI symptoms Peripheral neuropathy Bilateral deafness Tinnitus Peripheral edema Decreased cold sensation 	 Chronic pain Peripheral neuropathy Neuropathic shuffling gait Lethargy Temperature intolerance Tinnitus Hearing loss GI symptoms
	Leukocyte AGA enzyme activity at baseline (nmol/hr/mg protein)	0.10*	2.38**	0.58**	0.46**
	Plasma lyso-Gb3 at baseline (nM)	202***	8***	147***	92***
	Comment	IgA deposits in kidney biopsy	Cardiac variant, not a classic Fabry male		
ayo Lab, ref range ≥23.1 nmol/hr/mg Rupar Lab, ref range 24-56 nmol/hr/mg Reference value ≤ 2.4 nM A: α-galactosidase A; Lyso-Gb3: Globotriaosylsphingosine; G	 	n-A			AVROE

(plate

11

Patient 1: 87% substrate reduction in kidney biopsy at 1 year

4.5

Δ 3.55 3.5 Mean Number of Gb3 Inclusions per PTC Average 3 number of Gb3 2.5 inclusions per peritubular 2 capillary (PTC) 1.5 Unpaired t-test for difference between 1 n=55 PTCs at baseline vs. n=101 PTCs at 1 year; p < 0.0001 0.47 0.5 Error bar represents the standard . deviation 0 **Baseline** 1 Year (48 weeks)

Baseline: The last available, non-missing observation prior to AVR-RD-01 infusion Note: With respect to Fabry disease, Gb3 inclusions per PTC is interchangeable with GL-3 inclusions per KIC


FAB-201-1: First patient in FAB-201 clinical trial

PTC: Peritubular Capillary; Gb3: Globotriaosylceramide; GL-3: Globotriaosylceramide; KIC: Kidney Interstitial Capillary





Patient 1: Multiple data trends sustained up to 22 months




13

Note: Visualization of multiple biomarkers adjusted to utilize the same statistical scaling ratio across biomarkers (as compared to prior presentation)

FAB-201 FABRY PHASE 2 – Cardiac Variant

14


Patient 2: Multiple data trends sustained up to 1 year*



Note: As patient #2 is a cardiac variant of Fabry disease, this patient had a skin biopsy score of 0 (trace or no accumulation) at baseline and at 6 months Note: Visualization of multiple biomarkers adjusted to utilize the same statistical scaling ratio across biomarkers (as compared to prior presentation) * Latest data points for this patient are at the 1-year follow-up which = 48 weeks per protocol




Patient 3: Data up to 1 year* suggest trend towards durable engraftment





Patients 1-4: Plasma and leukocyte enzyme activity sustained up to 22 months

Patient #4 dosed using plato[™]





17

Patients 1-4: Plasma lyso-Gb3 reduction sustained up to 18 months



• Note: Patient #2 has normal substrate, consistent with late-onset cardiac variant phenotype

Two AVR-RD-01 Fabry clinical trials

9 patients dosed across Phases 1 and 2



PHASE 1 Investigator-Sponsored Trial*

Patients

n = 5 (fully enrolled) On ERT > 6 months prior to enrollment 18 - 50 year-old males

Key Objectives

Safety and preliminary efficacy

FAB-201 = AVRO-RD-01-201 Study * Sponsored by FACTs team (Fabry Disease Clinical Research and Therapeutics) in Canada ERT: Enzyme Replacement Therapy PHASE 2 WRO – FAB-201 Trial

Patients

n = 8-12 (4 patients dosed to-date} Treatment-naive 16 - 50 year-old males

) 🕐 🍧

Key Objectives

Safety and efficacy





Fabry
Phase 1
Patient
Characteristics

ERT-Treated Fabry Patients

		PATIENT 1	PATIENT 2	PATIENT 3	PATIENT 4	PATIENT 5
stics	Age of symptom onset / diagnosis	18 / 37 years	9 / 29 years	10 / 0 years	7 / 4 years	10 / 14 years
	Years on ERT	11 years	6 years	4 years	11 years	2 years
	Age dosed with AVR-RD-01	48 years	39 years	40 years	37 years	30 years
	Mutation	c.962A>G (p.Q321R)	c.1033T>C (p.S345P)	c.427G>C (p.A143P)	c.427G>C (p.A143P)	(p.Y134S)
	Primary disease signs and symptoms	 Kidney disease Cardiac disease GI pain GI diarrhea Angiokeratoma Insomnia 	 Kidney disease Cardiomyopathy Hypohidrosis Corneal verticillata Peripheral neuropathy GI symptoms Angiokeratoma Lymphedema Acroparesthesia 	 Cardiac Disease Tinnitus Headaches Dizziness Acroparesthesia 	 Cardiac Disease Hypohidrosis Tinnitus Corneal verticillata Angiokeratoma GI symptoms 	 Kidney disease Hypertension Hypohidrosis Tinnitus Migraines Impaired hearing Angiokeratoma Sleep apnea Asthma Depression
	Leukocyte AGA activity at baseline (nmol/hr/mg protein)	2.1*	1.1*	0.6*	2.2*	1.0*
	Plasma lyso-Gb3 at baseline (nM)	25**	26**	59**	29**	16**
	ERT discontinuation status	18 months after gene therapy dose		Did not resume ERT after gene therapy dose	6 months after gene therapy dose	

* Rupar Lab, ref range 24-56 nmol/hr/mg ** Reference value ≤ 2.4 nM

Note: AGA: α-galactosidase A; ERT: Enzyme Replacement Therapy; GI: Gastrointestinal; Lyso-Gb3: Globotriaosylsphingosine





Patients 1-5: Plasma lyso-Gb3 reduction sustained up to 32 months

All patients who have discontinued ERT remain off ERT*






Patients 1-5: Leukocyte and plasma enzyme activity sustained up to 32 months Consistent trends across all patients, 4 patients > 1 year





22

VCN stable at 32 months with consistent trend across all other patients 4 patients with 1+ years data



VCN: Vector Copy Number



Patient 1: Kidney function stable at 32 months



(+)

Phase 1 Fabry (5 patients) and FAB-201 (4 patients)

No unexpected safety events or trends identified

Note: Safety data cut November 26, 2019 AE: Adverse Event; SAE: Serious Adverse Event NOTE: AVR-RD-01 is an investigational gene therapy

) No SAEs related to AVR-RD-01 drug product

AEs and SAEs reported

Phase 1 AEs (n = 128):

 Generally consistent with myeloablative conditioning, underlying disease or pre-existing conditions

FAB 201 AEs (n = 98):

- Generally consistent with myeloablative conditioning, underlying disease or pre-existing conditions
 - Grade 1 or 2 (n = 72)
 - Grade 3 or 4 (n = 30)

Anti-AGA antibodies

Pre-existing low titers detected in 4 patients

Phase 1SAEs (n = 2):

- Febrile neutropenia (grade 3)
- Thrombophlebitis (grade 2)

FAB 201 SAEs: (n = 4)

Pre-treatment and prior to conditioning

• Seizure (grade 2)


Post-treatment

- Dehydration, nausea, vomiting (grade 3)
- Febrile neutropenia (2 patients, grade 3 & 4)



Fabry disease target product profile (T.P.P.)

Potential attributes intended to support first-line use



ERT: Enzyme Replacement Therapy

Note: Potential attributes represent desired target product profile, and are not intended, and should not be interpreted, to be attributes of AVROBIO's current investigational gene therapies, which are being studied for safety and efficacy and have not been approved by the FDA or any other regulatory body.

Building commercial capabilities

44+ product launches, including 1 gene therapy



- Led commercial teams for LSDs at SanofiGenzyme
- Head of Commercial at SOBI, a rare disease company




Jose Gomez SVP, Global Market Access & Value



- Led global strategic marketing and global market access functions at AveXis
- Led market access, global strategic pricing and reimbursement functions for LSDs at Shire



Sean Ring VP, Head of Commercial Operations



 Built out market development and commercial ops at Editas, Zafgen, Cubist, Shire, Biogen



Ramesh Arjunji VP, Global Health Economics and Outcomes Research / Value



- Led value demonstration for insurers globally at AveXis
- Significant access and reimbursement responsibilities at leading global biotech companies







UNMET NEEDS:



Kidney function

Unmet needs: renal Fanconi syndrome, proteinuria, chronic kidney disease, kidney failure

A Vis

Vision

Unmet needs: corneal cystine accumulation, photophobia, involuntary eyelid closure

Endocrine disorders

Unmet needs: softening/weakening of bones, bone pain, rickets, long bone deformations, hypophosphatemia, delayed growth, hypothyroidism, pancreatic insulin insufficiency, diabetes, infertility



CNS complications

Unmet needs: myopathy, hypotonia, tremors, difficulty swallowing, neurodevelopmental issues (speech and walking delay and cognitive impairment)

Everyday burden of illness and life expectancy

Unmet needs: medications multiple times per day that cause GI discomfort and sulfur body and breath smell, shortened lifespan

Sources: Ariceta G et al, Nephrol Dial Transplant, 2015; Elmonem M et al, Orphanet Journal of Rare Diseases, 2016; Gahl et al, NEJM, 2002; Bois et al, J Med Genet, 1976 CNS: Central Nervous System; GI: Gastrointestinal

Goals for gene

therapy in


cystinosis





Cystinosis caused by defective gene that encodes cystinosin, an exporter protein

Cystine crystals build up in lysosomes causing tissue and organ damage






Drug product-derived macrophages restore normal cystine recycling

Mechanisms of action

Macrophages with CTNS transgene restore cystine recycling to CTNS-ve cells via:
1. Tunneling nanotubes – transfer of corrected lysosomes, cystinosin, CTNS mRNA
2. Exosomes / Microvesicles – transfer of cystinosin, CTNS mRNA
Net result: Corrected lysosomes in cells throughout the body



Allogeneic transplant demonstrated stabilized renal function, corrected polyuria and improved photophobia


Allogenic HSC Transplant


University Hospital Leuven

- 16 year old male
- Diagnosed at 2.7 years old, started on cysteamine
- Age 15 years cysteamine toxicity
- Age 16 years fully matched HLA transplant
- Acute GvHD
- First few months
 - Kidney function stabilized
 - Polyuria resolved
- 6 months
- Photophobia score reduced from 5 (unable to open eyes even inside dark room) to 0 (no photophobia)


Cystine crystal reduction (31%) in macrophages in gastric mucosa at 30 months post transplant


BEFORE TRANSPLANT





30 MONTHS POST TRANSPLANT





Arrows/arrowheads point to tissue macrophages



Elmonem M A et al, Am. J. Transplant, 2018; HSC: Hematopoietic Stem Cell; HLA: Human Leukocyte Antigen; GvHD: Graft vs Host Disease



Investigator-sponsored* study of AVR-RD-04 in cystinosis patients

First patient dosed



PHASE 1/2 Investigator-Sponsored Trial*

Patients

Up to 6 patients Adults and adolescents Cohorts 1-2 ≥18 years; Cohort 3 ≥14 years Male and Female On oral and ophthalmic cysteamine

> Key Objectives Safety and efficacy

* Sponsored by University of California, San Diego Note: AVR-RD-04 aka CTNS-RD-04





	PATIENT 1
Age of symptom onset / diagnosis	0 year / 8 months
Age dosed with AVR-RD-04	20 years
Gender	Male
Mutation	Allele 1: LDM ₁ Allele 2: Nt1035 (insC)
Primary disease signs and SoC treatment related symptoms, including	 Fanconi syndrome Polyuria Corneal abnormalities Mild photophobia Vomiting
Granulocyte Cystine levels at baseline (nmol half cystine per mg protein)*	7.8
Comments	NO kidney transplant
	 Cysteamine 1125 mg p.o. every 12 h/day since 2009; discontinued prior to AVR-RD-04 infusion Cysteamine eyedrops 4-5x/day Concomitant medications not listed

Note: AVR-RD-01 aka CTNS-RD-04



+

Phase 1/2 Cystinosis 1 patient dosed

No unexpected safety events or trends identified

No AEs or SAEs related to AVR-RD-04 drug product

- No SAEs reported

AEs reported

- · Consistent with myeloablative conditioning and underlying disease
- N = 22 (moderate = 9, mild = 13)

Pre-treatment and prior to conditioning (n = 6, not all events listed)

- Diarrhea, hypokalemia, dizziness
- Dehydration, vomiting

Post-treatment (n = 16, not all events listed)

- Alopecia, intermittent diarrhea, vomiting
- Mucositis, intermittent febrile neutropenia, intermittent epistaxis
- Intermittent blurry vision, intermittent hypokalemia, mucoceles
- Thrombocytopenia

Note: Safety database cut as of January 27, 2020 AE: Adverse Event; SAE: Serious Adverse Event




CYSTINOSIS PHASE 1/2



AVROBIC

35

Patient 1: Initial data indicate positive trends across multiple measures



Asymptomatic Heterozygous Carrier Granulocyte Cystine Range: 0.2 – 1 .9 µmol half cystine/g protein

Source: Gertsman I et al., Clinical Chemistry, 2016


VCN: Vector Copy Number; CTNS: Cystinosin, Lysosomal Cystine Transporter; mRNA: Messenger Ribonucleic Acid; eGFR: Estimated Glomerular Filtration Rate; SCr: Serum Creatinine *Data obtained using a novel experimental methodology utilizing in vivo confocal microscopy, to image crystals in the skin behind the ear **CYSTINOSIS PHASE 1/2**



Patient 1: Reduced treatment burden at 6 months

Number of Medications and Supplements

(max per day)









Gaucher Disease

AVR-RD-02



UNMET NEEDS:



Bone-related manifestations

Hemoglobin levels and platelet counts

Unmet needs: anemia, thrombocytopenia, easy bruising, bleeding

Unmet needs: bone pain, avascular necrosis, bone crisis, osteoporosis, fractures, joint destruction, skeletal abnormalities

Goals for gene therapy in Gaucher Type 1 Disease

\bigcirc

Hepatosplenomegaly

Unmet needs: enlarged liver, enlarged spleen

CNS complications

Unmet needs: Increased risk of GBA-Parkinson's disease



Everyday burden of illness, and life expectancy

Unmet needs: fatigue, pain, lung disease, biweekly infusions, shortened lifespan



Sources: Grabowski G et al, Online Metabolic and Molecular Bases of Inherited Disease, 2018; Weinreb N et al, AJH, 2008; Pastores G et al, Semin Hematol, 2004 CNS: Central Nervous System; GBA: gene coding for glucocerebrosidase

Long-term follow-up study highlights significant unmet need in Gaucher Type 1

Despite standard-of-care ERT, **disease progression** continues and **unmet need** remains.

Incomplete therapeutic response is common:

- 60% of patients failed to achieve at least one of the six therapeutic goals evaluated after 4+ years of ERT¹
- A clinically significant percentage of patients continue to exhibit bone pain, organomegaly and cytopenia after 10 years of ERT²
- 25% of patients continue to suffer from physical limitations after two years of ERT, primarily due to bone disease³

Persistence after 10 years ERT [†]	Non-splenectomized Patients	Splenectomized Patients				
Anemia	12.4%	8.8%				
Thrombocytopenia*	22.7%	0.7%				
Splenomegaly*	38.3%	N/A				
Hepatomegaly*	14.3%	18.8%				
Bone Pain	42.9%	62.5%				
Bone Crisis	7.4%	16.7%				

* Higher persistence rates observed when more severe manifestations were present at baseline


[†] Persistence refers to the presence of anemia, bone pain, bone crisis, or at least moderate thrombocytopenia, splenomegaly, or hepatomegaly, present after 10 years of ERT among those with baseline involvement of these parameters (from a registry of 757 GD1 patients; Weinreb et al., 2013).

Following 10 years of treatment, ~26% of patients were receiving between 45-150 U/kg EOW, and 96% of these individuals were receiving doses between 45-90 U/kg EOW.

Sources: ¹Weinreb N et al. Amer J Hematol, 2008; ²Weinreb N et al. J Inherit Metab Dis, 2013; ³Giraldo P et al. Qual Life Res, 2005. GD1: Gaucher Disease Type 1; SOC: Standard of Care; ERT: Enzyme Replacement Therapy; EOW: Every Other Week



GAU-201: Phase 1/2 study in Gaucher Type 1 patients



Patients

n = 8 - 16 Type 1 Gaucher Treatment naïve or on ERT 16 - 35 year-old Male and Female

Key Objectives

Safety, Engraftment, Efficacy, ERT-independence



()

GAU-201: AVR-RD-02 Study; ERT: Enzyme Replacement Therapy



Pompe disease

AVR-RD-03



TO PREVENT OR IMPROVE:



Pulmonary function

Unmet needs: respiratory insufficiency, chronic respiratory infections, sleep apnea, artificial ventilation



Physical endurance and strength

Unmet needs: proximal myopathy, progressive muscle weakness in diaphragm, trunk and lower limbs, wheel-chair bound



CNS complications

Unmet needs: neuromuscular control, reduction in executive function, cognitive impairment

GI complications

Unmet needs: macroglossia (childhood onset), difficulty chewing and swallowing, GI symptoms, including irritable bowel-like symptoms



Everyday burden of illness, and life expectancy

Unmet needs: fatigue, hepatomegaly, independent living, biweekly infusions, shortened lifespan



Sources: Barba-Romero M et al, Rev Neurol, 2012; Dasouki M et al, Neurol Clin, 2014; Hagemans M et al, J Neurol, 2007; Musumeci O et al, Eur J of Neurol, 2018

Goals for gene therapy in **Pompe Disease**

Pompe lentiviral gene therapy program advancing Integrated three-part approach




THE CHALLENGE

- Pompe requires 20x more ERT than Fabry or Gaucher
- Requires GAA activity restored to muscle and CNS

AVROBIO's APPROACH

- Potent transgene promoter
- GILT uptake tag
- Bu90-TDM for CNS impact

GILT-tagged Recombinant Human (rh)GAA impacts levels of stored glycogen compared to non GILT-tagged Recombinant Human (rh)GAA in a Pompe mouse model







• GILT: Glycosylation-Independent Lysosomal Targeting

• Sources: Burton B et al, J Pediatr, 2017; Ausems M et al, Eur J Hum Genet, 1999; Gungor D et al, Orphanet J Rare Dis, 2011; Maga JA et al, J of Bio Chem, 2013; Bartelink, Lancet Haematol, 2016.


GILT and GILT mutant v1 reduce glycogen by >99% in heart (+)






44

Glycogen and GILT and GILT mutant v1 similar to wildtype mice GILT tag is essential for glycogen clearance in CNS





AVROBIO (plate)

45

*** P<0.001



plato[™]

AVROBIO's foundation designed to scale gene therapy worldwide

State-of-the-art technologies including automated manufacturing platform

+ Optimized for performance + Redefines manufacturing best practices






AVROBIO (plate

47

plato[™]: Three upgrades designed to optimize potency, safety and durability



plato™ UPGRADE 1

VECTOR UPGRADE: Metrics compared to academic process

FAB-201 patient #4 drug product data with plato™

 2.2x

 Increase vs. Mean


 Mean = 4.8

 6.4
 5.3
 2.6
 10.7


 PATIENT 1
 PATIENT 2
 PATIENT 3
 PATIENT 4

Enzyme Activity (nmol/hr/mL)

FAB-201



FAB-201




VCN: Vector Copy Number; FAB-201: AVR-RD-01 Study NOTE: Data is from drug product



48



VECTOR UPGRADE: Metrics compared to academic process FAB-201 and AVR-RD-04 drug product data




49

NOTE: Data is from drug product


plato™ UPGRADE 2

PRECISION CONDITIONING UPGRADE: Targeted busulfan intended to balance optimal engraftment with enhanced safety Meta-analysis of 465 patients identified optimal exposure



plato™ UPGRADE 2


PRECISION CONDITIONING UPGRADE: Precision dosing via state-of-the-art patient therapeutic drug monitoring (TDM)



51


Notes: Illustrative only. AEs will vary patient by patient, see busulfan label for a complete list of side-effects. Ambulatory care based on oncology setting with higher intensity conditioning

PRECISION CONDITIONING UPGRADE: Rapid neutrophil and platelet recovery with minimal lymphocyte depletion using Busulfan TDM




plato™ UPGRADE 2

PRECISION CONDITIONING UPGRADE: Designed to access "hard-to-reach" compartments



PRECISION CONDITIONING UPGRADE: Designed to access "hard-to-reach" compartments, including the brain






MRI: 54 year old with Fabry disease demonstrating white matter lesions (WMLs)

MRI: Magnetic Resonance Imaging; ERT: Enzyme Replacement Therapy; WMLs: White Matter Lesions; HSC: Hematopoietic Stem Cell

Source: Buechner S, J. Neurol, Neurosurg, Psychiatry, 2008



GFP: Marker of engrafted cells Iba1: Marker of microglia cells DAPI: Nuclear stain irrespective of cell type

Global microglial coverage of mouse brain at 4 months post gene-modified HSC transplantation

- Widespread engraftment in regions critical for cognitive, motor, olfactory, and visual function
- Engrafted microglia/microglia-like cells have comparable morphology and classical lineage markers with endogenous microglia



AUTOMATION UPGRADE: Automated, scalable manufacturing system





Expanded Scale

Potential to reach thousands of patients per year



Broader Reach

Portable platform designed for flexible global production using low grade clean rooms



High Quality

Automated, closed system designed to improve quality and consistency



Enhanced Convenience

Cryopreservation simplifies logistics and patient scheduling




Lower Costs

Designed to create efficiencies in vector design / scalable cell and vector production




AUTOMATION UPGRADE: Designed to deliver large-scale manufacturing

Differentiated, cost-effective approach




AUTOMATION UPGRADE: Global manufacturing established Automated systems operational in 3 sites with 4th in progress




AUTOMATION UPGRADE: Poised to manufacture at scale



Designed to optimize potency and safety, and overcome historic CMC bottlenecks





4.6

Patient 4

Patient 2

Patient 1

Patient 3

Patient 1

Patient 2

Patient 3

57.9


AVROBIO (plate

59

Patient 4

Milestones anticipated across the pipeline in 2020

Clinical activities and timelines subject in all respects to ongoing and evolving COVID-19 pandemic*



AVROBIO to hold first R&D Day in 2020

AVROBIC

60

* For additional information, see the Company's Current Report on Form 8-K filed with the SEC on March 30, 2020, and the Company's risk factor related to COVID-19 in the Company's Annual Report on Form 10-K filed with the SEC on March 16, 2020.






Appendix

Hematopoietic reconstitution occurs in two distinct phases igoplus

A few thousand long-term engrafting cells stably sustain levels of transgene product



First wave of short-term progenitor cells start to exhaust with

(+)

Precedent for use of kidney biopsy data for FDA approval of drug candidate for Fabry disease

Migalastat approved on % reduction in GL-3 inclusions per KIC as compared to placebo

45 Amenable patients* (16 males / 29 females)



Group	Migalastat (BL –M6)	Placebo (BL –M6)			
Males (N=16)	5/7 (71%) -1.10 (-1.94, -0.02)	4/9 (44%) -0.03 (-1.00, 1.69)			
Patients with baseline GL-3 ≥ 0.3	7/9 (78%)	2/8 (25%)			
(N=17; 9 males, 8 females)	-0.91 (-1.94, 0.19)	-0.02 (-1.00, 1.69)			
Patients with baseline GL-3 < 0.3	6/16 (38%)	7/12 (58%)			
(N=28; 7 males, 21 females)	-0.02 (-0.10, 0.26)	-0.05 (-0.16, 0.14)			


Treatment Group		Baseline Median (min, max)	Month 6 Median (min, max)	Change from Baseline Median (min, max)						
Average number of GL-3 inclusions per KIC (N=13)										
Galafold	7	3.6 (0.2, 6.0)	2.6 (0.1, 6.0)	-0.7 (-1.7, 1.2)						
Placebo	6	1.8 (0.1, 2.8)	2.0 (0.05, 4.3)	-0.04 (-0.5, 1.5)						

7/9 males ≥ 50% reduction

(at 6 months from baseline)

28% average reduction

(at 6 months from baseline)



Classic Fabry disease (AGA activity <1%)

Classic Fabry patient level data

0-6 months randomized clinical trial and 6-12 months open label extension

	Male Patients with the Classic Phenotype													
	Migalastat (Months 0-24)							Placebo (Months 0-6) \rightarrow Migalastat (Months 6-24)						
	#1	#2	#3	#4	#5	#6	#7	#8	#9	#10	#11	#12	#13	#14
PTC GL-3 inclusions at BL	0.16	0.03	n/a	5.69	1.22	n/a	2.88	2.41	1.55	0.16	0.03	0.11	0.94	0.88
Change in PTC GL-3 inclusions from BL to M6	-0.08	0.01	n/a	-1.77	-1.10	n/a	-1.25	1.21	-0.21	0.01	0.09	-0.07	1.94	-0.83
Change in PTC GL-3 inclusions from BL/M6 ^b to M12	-0.12	n/a	n/a	-1.92	n/a	n/a	-0.81	-0.94	-1.13	-0.09	-0.05	n/a	-2.28	0.06

46% average reduction

(average of patients with 12 month data)



NOTE: For informational purposes; differences exist between trial designs and subject populations; AVROBIO has not conducted any head-to-head trials comparing migalastat to AVR-RD-01




FABRY PHASE 1



Reduction of pre-existing anti-ERT drug IgG antibodies following AVR-RD-01

Suggests potential as a therapeutic option independent of pre-existing antibodies



ERT: Enzyme Replacement Therapy; IgG: Immunoglobulin G; MPS-1: Mucopolysaccharidosis Type 1; IDUA: Iduronidase: SR-TIGET: San Raffaele Telethon Institute for Gene Therapy; LV: Lentiviral; rhIDUA: Recombinant Human alpha-L-Iduronidase

Similar Results Observed in Other Studies

San Raffaele Telethon Institute for Gene Therapy (SR-TIGET)

Change in pre-existing antibodies reported for Hurler disease (MPS-1)

- Ex vivo LV-CD34+ gene therapy with conditioning
- N = 6
- Evaluable patients (5/6) demonstrated sustained, supraphysiologic blood IDUA activity
- 4/5 prior ERT (rhIDUA) exposure (5-28 months)
- 4/5 pre-existing ERT-induced IgG antibodies
- 6/6 anti-rhIDUA IgGs undetectable 2 months post gene therapy

Source: Gentner B et al., Blood, 2019



(+)

New collaborations advancing leadership in lentiviral gene therapy



Fully Automated Bu-TDM Immunoassay

- AVROBIO and Saladax announced agreement to develop and validate Saladax's fully automated nanoparticle immunoassay kit
- Designed to work on most automated hospital analyzers
- Regular technician, 24/7 analysis possible with results anticipated in minutes using only microLs of blood
- Designed to analyze 10-100s samples per machine/hour
- Expected to eliminate Bu degradation errors as assay conducted in real-time at the point of care
- Scalable



Antibody-Drug Conjugate

- AVROBIO and Magenta announced research & clinical collaboration agreement to evaluate Magenta's preclinical CD117-targeted antibody conjugate to amanitin (MGTA-117) in conjunction with AVROBIO investigational gene therapies
- Designed to deplete only hematopoietic stem and progenitor cells
- Has shown promising data in non-human primates
- MGTA-117 currently in IND-enabling studies
- Each party retains commercial rights to its own programs